Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Taiyo Yakuhin Recalls Tetipline Due to Adverse Reactions
February 22, 2010
- Toho to Enhance Pharmacy Business by Acquiring Medical Brain
February 22, 2010
- BI to Make SSP Wholly-Owned Subsidiary
February 22, 2010
- Korosho's Proposal Regarding Generics Priced
February 22, 2010
- More Switch OTC Drugs Are Necessary to Stimulate Market: Mr Konja
February 22, 2010
- \170 Premium to Be Paid If Generics Dispensing Rate Exceeds 30%
February 22, 2010
- SSP: Sales Down Despite Good Sales of CHC Products
February 22, 2010
- Medical Fee Determination Process Needs to Be Revised: Mr Nagatsuma
February 22, 2010
- Take Comprehensive Measures to Prevent VTE Including Use of Anticoagulants: Dr Sakon
February 22, 2010
- JPA Concerned about Confusion among Pharmacists Regarding Three-Tiered Premiums
February 22, 2010
- Adcirca Useful for PAH with Low Incidence of ADRs: Prof. Sato
February 22, 2010
- 1st Meeting Held by Panel on Unapproved Drugs with Unmet Medical Need
February 22, 2010
- Healthcare Is Opportunity for Investment: Mr Wachi
February 22, 2010
- Doctors Assess MRs Based on Their Expertise
February 22, 2010
- DPJ Lawmaker Calls For Promotion of Pharma Industry
February 22, 2010
- FUJIFILM Embarks on Generics Business Aiming at ¥50.0 Bil. Sales in FY2014
February 22, 2010
- Novartis' Sales Up 8.2% in 2009 Driven by Diovan, Glivec
February 22, 2010
- Cost Necessary to Revitalize Healthcare Estimated by a Team: Dr Adachi
February 22, 2010
- GSK's Sales Up 22% in Japan
February 22, 2010
- 9 New Drugs to Be Reviewed on February 26
February 22, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…